Asosiy kontentga oʻtish
Maqola

Comprehensive genomic characterization of squamous cell lung cancers

Gad GetzThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, 02142, Massachusetts, USAStephen E. SchumacherDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.,Petar StojanovEli and Edythe Broad FoundationSachet ShuklaDepartment of Medical Oncology, Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.,Hailei ZhangDepartment of Medical Oncology, Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.,Kristian CibulskisEli and Edythe Broad FoundationNam H. PhoEli and Edythe Broad FoundationMatthew MeyersonEli and Edythe Broad FoundationEric S. LanderDepartment of Systems Biology, Harvard University, Boston, Massachusetts 02115, USA.,Helga ThorvaldsdottirEli and Edythe Broad FoundationBarbara TabakThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, 02142, Massachusetts, USANils GehlenborgThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, 02142, Massachusetts, USAAndrey SivachenkoEli and Edythe Broad FoundationMarc-Danie NazaireThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, 02142, Massachusetts, USAPei LinEli and Edythe Broad FoundationMichael NobleEli and Edythe Broad FoundationLihua ZouEli and Edythe Broad FoundationJim RobinsonThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, 02142, Massachusetts, USADoug VoetThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, 02142, Massachusetts, USARameen BeroukhimThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, 02142, Massachusetts, USAJill MesirovEli and Edythe Broad FoundationDouglas VoetEli and Edythe Broad FoundationMarcin ImielinskiThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, 02142, Massachusetts, USAPeter S. HammermanEli and Edythe Broad FoundationPeter S. HammermanThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, 02142, Massachusetts, USAHuy NguyenEli and Edythe Broad FoundationWendy WincklerGenetic Analysis Platform, The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, 02142, Massachusetts, USAAaron McKennaEli and Edythe Broad FoundationLynda ChinDepartment of Medical Oncology, Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.,Andrew CrenshawEli and Edythe Broad FoundationJuok ChoThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, 02142, Massachusetts, USAElena HelmanEli and Edythe Broad FoundationSpring Yingchun LiuThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, 02142, Massachusetts, USAScott L. CarterThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, 02142, Massachusetts, USAGordon SaksenaThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, 02142, Massachusetts, USAMichael S. LawrenceEli and Edythe Broad FoundationDaniel DiCaraEli and Edythe Broad FoundationRui JingThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, 02142, Massachusetts, USABryan HernandezEli and Edythe Broad FoundationAndrew D. CherniackEli and Edythe Broad FoundationAndrey SivachenkoThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, 02142, Massachusetts, USAStephen E. SchumacherThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, 02142, Massachusetts, USARameen BeroukhimEli and Edythe Broad FoundationBarbara TabakThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, 02142, Massachusetts, USABruce E. JohnsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.,Chang-Jiun WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.,Peter S. HammermanEli and Edythe Broad FoundationDavid KwiatkowskiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.,Bruce JohnsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.,Peter S. HammermanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.,Matthew MeyersonEli and Edythe Broad FoundationLynda ChinDepartment of Genomic Medicine, Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.,Eric S. LanderDepartment of Biology, Massachusetts Institute of Technology, Cambridge, 02142, Massachusetts, USAEric S. LanderThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, 02142, Massachusetts, USACarrie SougnezDepartment of Systems Biology, Harvard University, Boston, Massachusetts 02115, USA.,Gad GetzThe Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, 02142, Massachusetts, USACarrie SougnezDepartment of Systems Biology, Harvard University, Boston, Massachusetts 02115, USA.,Stacey GabrielGenetic Analysis Platform, The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, 02142, Massachusetts, USAKristin ArdlieGenetic Analysis Platform, The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, 02142, Massachusetts, USARobert C. OnofrioGenetic Analysis Platform, The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, 02142, Massachusetts, USAGad GetzGenetic Analysis Platform, The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, 02142, Massachusetts, USAWendy WincklerGenetic Analysis Platform, The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, 02142, Massachusetts, USAMarcin ImielinskiEli and Edythe Broad FoundationMatthew MeyersonDepartment of Pathology, Harvard Medical School, Boston, 02115, Massachusetts, USAMarcin ImielinskiDepartment of Pathology, Harvard Medical School, Boston, 02115, Massachusetts, USAYongjun ZhaoCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Andrew J. MungallCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Angela TamCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Karen MungallCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Andy ChuCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,An HeCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Miruna BalasundaramCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Elizabeth ChunCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Richard VarholCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Robert A. HoltCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Jacqueline E. ScheinCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,A. Gordon RobertsonCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Andy ChuCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Carrie HirstCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Marco A. MarraCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Martin HirstCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Eric ChuahCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Robin J. N. CoopeCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Hye-Jung E. ChunCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Dominik StollCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Yaron S. N. ButterfieldCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Ka Ming NipCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Haiyan I. LiCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Erin PleasanceCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Jared R. SlobodanCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Ranabir GuinCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Nina ThiessenCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Gordon RobertsonCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Andy MungallCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Darlene LeeCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Thomas ZengCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Michael MayoCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Andy ChuSRA International, Fairfax, Virginia 22033, USA.,Richard CorbettCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,Richard A. MooreCanada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z, Canada.,
2012en
ABI

Annotatsiya

Lung squamous cell carcinoma is a common type of lung cancer, causing approximately 400,000 deaths per year worldwide. Genomic alterations in squamous cell lung cancers have not been comprehensively characterized, and no molecularly targeted agents have been specifically developed for its treatment. As part of The Cancer Genome Atlas, here we profile 178 lung squamous cell carcinomas to provide a comprehensive landscape of genomic and epigenomic alterations. We show that the tumour type is characterized by complex genomic alterations, with a mean of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy number alteration per tumour. We find statistically recurrent mutations in 11 genes, including mutation of TP53 in nearly all specimens. Previously unreported loss-of-function mutations are seen in the HLA-A class I major histocompatibility gene. Significantly altered pathways included NFE2L2 and KEAP1 in 34%, squamous differentiation genes in 44%, phosphatidylinositol-3-OH kinase pathway genes in 47%, and CDKN2A and RB1 in 72% of tumours. We identified a potential therapeutic target in most tumours, offering new avenues of investigation for the treatment of squamous cell lung cancers. Comprehensive analyses of 178 lung squamous cell carcinomas by The Cancer Genome Atlas project show that the tumour type is characterized by complex genomic alterations, with statistically recurrent mutations in 11 genes, including TP53 in nearly all samples; a potential therapeutic target is identified in most of the samples studied. The Cancer Genome Atlas consortium has analysed 178 lung squamous cell carcinomas, a common type of lung cancer for which comprehensive genomic analyses have not previously been available. The researchers report that this tumour type is characterized by complex genomic alterations, with recurrent mutations in 18 genes, including TP53 in nearly all samples. They also report frequent mutations in squamous differentiation genes. Collectively, these analyses identify potential therapeutic targets worthy of further investigation.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba